{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:14:51Z","timestamp":1789226091507,"version":"build-2803163510"},"reference-count":40,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Treatment guidelines recommend rapid antiretroviral therapy (ART) initiation among eligible people with HIV to improve treatment outcomes and reduce HIV transmission. Bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF), an integrase strand transfer inhibitor\u2010based single\u2010tablet regimen, is recommended for rapid start in US and European guidelines. This systematic literature review synthesized evidence on the efficacy, safety and effect on patient\u2010reported outcomes (PROs) of B\/F\/TAF rapid start among newly diagnosed people with HIV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>MEDLINE, Embase, Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials databases were searched in January 2024, supplemented by searches of conference proceedings and clinical trial records. English\u2010language interventional studies of B\/F\/TAF rapid start among ART\u2010na\u00efve people with HIV reporting efficacy, safety or PROs were eligible. Study quality was assessed using York Centre for Reviews and Dissemination or Risk Of Bias In Non\u2010randomized Studies of Interventions checklists. Results were synthesized narratively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across eight included studies, 745 people with HIV received B\/F\/TAF rapid start, 171 received rapid start comparators and 255 received non\u2010rapid start comparators. At Weeks 24 and 48, 80%\u201394% and 74%\u201396% of people with HIV treated with B\/F\/TAF rapid start achieved viral load &lt;50 copies\/mL, respectively. Treatment discontinuation due to adverse events was 0%\u20133%, and grade 3\/4 adverse events occurred in 0%\u20133% of people with HIV receiving B\/F\/TAF rapid start. Rapid start improved engagement in care over traditional non\u2010rapid start approaches, and B\/F\/TAF rapid start reduced anxiety and improved quality of life among people with HIV. Limitations of the review included heterogeneous study definitions of \u201crapid start\u201d and limited data availability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>B\/F\/TAF rapid start was efficacious, safe and associated with high engagement in care and improved PROs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hiv.70065","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T03:28:52Z","timestamp":1750908532000},"page":"1375-1394","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Rapid start with bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/\n                    <scp>TAF<\/scp>\n                    ) as initial treatment in people with human immunodeficiency virus\u20101 (\n                    <scp>HIV<\/scp>\n                    \u20101): A systematic literature review of clinical and patient\u2010reported outcomes"],"prefix":"10.1111","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2914-959X","authenticated-orcid":false,"given":"Jade","family":"Ghosn","sequence":"first","affiliation":[{"name":"APHP.Nord, H\u00f4pital Bichat Claude Bernard, Service des Maladies Infectieuses  Paris France"},{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM UMR 1137 IAME  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Chow","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Gandhi","sequence":"additional","affiliation":[{"name":"University of California San Francisco  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"G\u00f3rgolas","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Jim\u00e9nez D\u00edaz  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4648-7657","authenticated-orcid":false,"given":"Aws","family":"Al\u2010Hayani","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Jim\u00e9nez D\u00edaz, University Hospital  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansel","family":"Tookes","sequence":"additional","affiliation":[{"name":"University of Miami \u2013 Miller School of Medicine  Miami Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Lee","sequence":"additional","affiliation":[{"name":"Costello Medical  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily F.","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Costello Medical  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Malebranche","sequence":"additional","affiliation":[{"name":"Gilead Sciences  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Alvarez","family":"Bognar","sequence":"additional","affiliation":[{"name":"Gilead Sciences  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5605-1425","authenticated-orcid":false,"given":"Bhumi","family":"Gandhi\u2010Patel","sequence":"additional","affiliation":[{"name":"Gilead Sciences  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Dai","sequence":"additional","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"The Urgency of Now: AIDS at a Crossroads. Geneva.2024."},{"key":"e_1_2_10_3_1","unstructured":"Treatment goals: adult and adolescent antiretroviral therapy.2016.https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv\u2010clinical\u2010guidelines\u2010adult\u2010and\u2010adolescent\u2010arv\/treatment\u2010goals\u2010adult\u2010and\u2010adolescent. Accessed 08\/02\/2024."},{"key":"e_1_2_10_4_1","unstructured":"Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in adults and adolescents with HIV.2019.https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/archive\/AdultandAdolescentGL_2021_08_16.pdf. Accessed 08\/02\/2024."},{"key":"e_1_2_10_5_1","unstructured":"European AIDS Clinical Society.EACS guidelines version 12.0.2023."},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17025"},{"key":"e_1_2_10_7_1","volume-title":"Consolidated guidelines on HIV prevention, Testing, Treatment, Service delivery and monitoring: recommendations for a public health approach","author":"World Health Organization","year":"2021"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001671"},{"issue":"6","key":"e_1_2_10_9_1","article-title":"Rapid initiation of antiretroviral therapy for people living with HIV","volume":"6","author":"Mateo\u2010Urdiales A","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-023-04058-4"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2022.0039"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.16.3.18640"},{"issue":"1","key":"e_1_2_10_13_1","first-page":"1","article-title":"Individual and contextual factors influencing patient attrition from antiretroviral therapy care in an urban community of Lusaka, Zambia","volume":"15","author":"Musheke M","year":"2012","journal-title":"J Int AIDS Soc"},{"key":"e_1_2_10_14_1","volume-title":"Implementing and scaling up undetectable = untransmittable (U=U): a resource guide","author":"Centers for Disease Control and Prevention Division of Global HIV and TB","year":"2024"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13593"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30080-3"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2024-056202"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02533-18"},{"key":"e_1_2_10_19_1","unstructured":"BIKTARVY\u00ae Prescribing Information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/210251Orig1s020lbl.pdf. accessed: 11\/1\/2021."},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00151-0"},{"key":"e_1_2_10_21_1","doi-asserted-by":"crossref","unstructured":"BenidirB SanchezLP SalunkheV et al.Impact of rapid initiation of antiretroviral therapy on retention in care in the Southern United States.2022. IDWeek.","DOI":"10.1093\/ofid\/ofac492.1103"},{"key":"e_1_2_10_22_1","doi-asserted-by":"crossref","unstructured":"WhitlockG FidlerS ClarkeA et al.A randomised control trial of BIC\/F\/TAF vs DRV\/c\/F\/TAF in context of HIV test\u2010and\u2010treat.2023. European AIDS Conference.","DOI":"10.1080\/25787489.2024.2400453"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/25787489.2024.2400453"},{"issue":"2","key":"e_1_2_10_24_1","first-page":"205","article-title":"Rapid art initiation using BIC\/FTC\/TAF and TDF+3TC+EFV in people with HIV in China","volume":"31","author":"Lv S","year":"2023","journal-title":"Top Antivir Med"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae012"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad008"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.107049"},{"key":"e_1_2_10_28_1","doi-asserted-by":"crossref","unstructured":"Hidalgo\u2010TenorioC SequeraS ColladoA et al.Bictegravir\/Emtricitavine\/Tenofovir alafenamide as first\u2010line treatment in na\u00efve HIV patients in a rapid\u2010initiation model of care: BIC\u2010NOW clinical trial.2023. European AIDS Conference.","DOI":"10.1016\/j.ijantimicag.2024.107164"},{"key":"e_1_2_10_29_1","unstructured":"UgarteA De La MoraL ChiviteI et al.Rapid initiation of antiretroviral therapy (ART) with bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) in a tertiary hospital in Barcelona Spain: a prospective clinical trial.2022. HIV Glasgow."},{"key":"e_1_2_10_30_1","unstructured":"Al\u2010HayaniAWM CarrilloI CabelloA et al.Starting antiretroviral therapy (ART) at the first HIV\u2010specialist appointment with or without baseline laboratory data with BIC\/FTC\/TAF (The BIFAST study).2022. International AIDS Conference."},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107164"},{"key":"e_1_2_10_32_1","unstructured":"SequeraS VivancosMJ VinuesaD et al.Impact of bictegravir\/emtricitabine\/tenofovir alafenamide on health\u2010related quality of life and economic outcomes in HIV care: a sub\u2010study of the BIC\u2010NOW clinical trial.2025. HIV Glasgow."},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae235"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30077-3"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-022-00734-5"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002937"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.1818"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002357"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6811e1"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2022.0169"},{"key":"e_1_2_10_41_1","unstructured":"BehrensGM AssoumouL LiegeonG et al.Integrase inhibitor versus protease inhibitor based therapy for people with advanced HIV disease (LAPTOP).2025. CROI 2025."}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T10:45:18Z","timestamp":1756723518000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.70065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1111\/hiv.70065"],"URL":"https:\/\/doi.org\/10.1111\/hiv.70065","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]},"assertion":[{"value":"2025-03-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}